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A B S T R A C T
Gastric cancer with peritoneal dissemination has poor clinical prognosis because of the presence of rich
stromal ﬁbrosis and acquired drug resistance. Recently, Angiotensin II type I receptor blockers such as
candesartan have attracted attention for their potential anti-ﬁbrotic activity. We examined whether
candesartan could attenuate tumor proliferation and ﬁbrosis through the interaction between gastric cancer
cell line (MKN45) cells and human peritoneal mesothelial cells. Candesartan signiﬁcantly reduced TGF-
β1 expression and epithelial-to-mesenchymal transition-like change, while tumor proliferation and stromal
ﬁbrosis were impaired. Targeting the Angiotensin II signaling pathway may therefore be an eﬃcient strat-
egy for treatment of tumor proliferation and ﬁbrosis.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Gastric cancer is a major global health concern, with an estimated
989,600 new cases andmore than 738,000 attributable deaths in 2011
[1]. A critical indicator for poor prognosis and themost frequentmeta-
static pattern in gastric cancer is peritoneal dissemination [2–4].While
clinical outcomes for gastric cancer patients with peritoneal dissemi-
nation have improvedwith advances in systemic and/or intraperitoneal
chemotherapy, desirable outcomes remain elusive [5–10]. Peritoneal
dissemination is characterized by cancer cell inﬁltration of and prolif-
eration within the peritoneal cavity, with accompanying extensive
stromal ﬁbrosis [11,12]. This leads to disorders including ileus, obstruc-
tive jaundice, and hydronephrosis. Therefore, new strategies for the
treatment of tumor proliferation and ﬁbrosis in peritoneal dissemina-
tion of gastric cancer are required.
Many studies suggest that the volume and composition of ﬁbrous
tissue in various organs are inﬂuenced by epithelial–mesenchymal
transition (EMT), which is characterized by a loss of epithelial cell
characteristics and gain of extracellular matrix-producing
myoﬁbroblast characteristics [13–15]. TGF-β1 signals play an im-
portant role in the progression of EMT and contribute to the
metastatic spread of cancer cells, inﬂuencing migration and inva-
sion [16,17]. Activated TGF-β1 can be found in tumor cells, ﬁbroblasts,
and peritoneal lavage ﬂuid, and previous studies have demon-
strated that TGF-β1 serum and tissue levels are signiﬁcantly
correlated with survival in gastric cancer patients [18–20]. There-
fore, targeting the effects of TGF-β1-induced EMT is important to
attenuate both metastasis and ﬁbrosis in gastric cancer.
Recent developments have shown that tumor progression results
from interactions between cancer cells and various stromal cells,
including endothelial cells, immune cells, and ﬁbroblasts in the tumor
microenvironment [21–23]. Bone marrow-derived ﬁbroblasts have
been shown to contribute to the tumor stromal environment and
inﬂuence tissue ﬁbrosis, being dubbed cancer-associated ﬁbro-
blasts (CAF) [24]. We have previously reported that TGF-β1-
mediated activation of human peritoneal mesothelial cells (HPMCs)
induces an EMT-like process whereby these cells adopt a ﬁbro-
blast or myoﬁbroblast-like phenotype process [25]. Furthermore,
activated HPMCs function as a source of CAFs, and drive the process
of ﬁbrosis [25]. HPMCs, which are classiﬁed as epithelial in the broad-
est sense of the term, form amonolayer of squamous epithelial cells
that cover the peritoneal cavity to form a serosal membrane which
serves as a protective anatomical barrier [26]. Previous studies have
suggested that CAFs produce stroma-modulating growth factors
including TGF-β1, VEGF, and HGF [27–29]. VEGF is a potent and
selective endothelial mitogen capable of inducing a rapid and com-
plete angiogenic response [27,28]. HGF may also be involved in
promoting the growth of various epithelial cells that express c-met,
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which is the HGF receptor [29]. Therefore, CAFs stimulate tumor
proliferation and induce ﬁbrosis [25]. Additionally, ﬁbrotic tumors
demonstrating advanced progression can be established in a sub-
cutaneous xenograft model using the gastric cancer cell line MKN45
in co-culture with HPMCs [25]. Therefore, the interaction between
cancer cells and HPMCs in the tumor microenvironment contrib-
utes to tumor proliferation and ﬁbrotic change.
Previously, several studies have identiﬁed that Angiotensin II can
promote cell proliferation during cancer development, and Angio-
tensin II type 1 (AT1) blockers (ARBs) may suppress this effect by
antagonizing the AT1 receptor [30–32]. Furthermore, ARBs have re-
cently attracted attention for their direct anti-ﬁbrotic activity. In
particular, ARBs may have the potential to inhibit ﬁbrotic change
in chronic kidney disease by reducing TGF-β1 expression [33–35].
Additionally, ARB treatment in patients withMarfan’s syndrome sig-
niﬁcantly slowed the rate of progressive aortic-root dilation, which
is caused by excessive TGF-β1 signaling [36]. These ﬁndings led us
to hypothesize that ARBs may effectively suppress tissue ﬁbrosis
during peritoneal dissemination of gastric cancer.
Therefore, this study aimed to assess whether ARBs attenuate
proliferation and ﬁbrosis in our established ﬁbrotic tumor model,
and also to clarify the mechanisms of Angiotensin II–AT1 receptor–
TGF-β1 molecular interactions in gastric cancer.
Materials and methods
Cell lines and cell culture
HPMCs were isolated from surgical specimens of human omentum as previ-
ously described [37]. Brieﬂy, small pieces of omentumwere surgically resected under
sterile conditions and were incubated in pre-warmed phosphate-buffered solution
(PBS) containing 0.125% trypsin/EDTA (Gibco/Invitrogen, USA) for 30 min at 37 °C.
The suspension was centrifuged at 1500 × g for 5 min. Collected cells were cul-
tured in RPMI-1640 medium (Gibco/Invitrogen) supplemented with 20% heat-
inactivated fetal bovine serum (FBS; Nichirei Bioscience Inc., Japan). The cells were
cultured at 37 °C in a humidiﬁed atmosphere of 5% CO2 in air. For the following ex-
periments, cells were used during the second or third passage after primary culture.
HPMCs possibly contaminated with endothelial cells or ﬁbroblasts at the time of
harvest were not used. Donors were not subjected to chemotherapy or radiation treat-
ment prior to surgery, and had no evidence of peritoneal inﬂammation and/or
malignancy. We used homogeneous HPMCs from a different donor for each exper-
iment. All patients provided written informed consent prior to participation in the
study. The gastric cancer cell lines used in this study wereMKN7, MKN74, andMKN45
which were purchased from American Type Culture Collection (Rockville, MD, USA).
Cells were maintained in RPMI-1640 medium supplemented with 10% FBS.
Chemicals
Angiotensin II and the AT1 receptor blocker, candesartan (CV-11974), and
telmisartan were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Mouse xenograft model
All animal experiments were performed according to Kanazawa University’s stan-
dard guidelines. Female immunocompromised BALB/c-nu/nu mice (Charles River
Laboratories Inc. Japan) at 4–6 weeks of age were maintained in a sterile environ-
ment. HPMCs were ﬁrst stained using a red ﬂuorescent dye PKH26 cell linker kit
(Sigma) according to the manufacturer’s instructions; the concentration of PKH26
during incubation was 4 μM. MKN45 cells were co-cultured with an equivalent
number of HPMCs for ﬁve days, and a total of 5 × 106 cells in 100 μL of RPMI-1640
were then subcutaneously injected into the dorsal side of eachmouse on day 0. Three
groups of 10 mice each were established: MKN45 cells alone (a total of 5 × 106 cells)
without candesartan, and MKN45cells co-cultured with HPMCs with or without
candesartan. Beginning on day 7, mice were administered 10 mg/kg of candesartan
daily by gavage. Animals were carefully monitored, tumors were measured every 4
days. The tumor volume (V) was calculated according to the formula V = AB2/2, where
A is the length of the major axis, and B is the length of minor axis.
Immunohistochemistry
Tumor specimens were ﬁxed in 10% neutral buffered formalin and embedded
in paraﬃn. Sections were stained with hematoxylin and eosin (H&E) and Azan stain
for assessment of ﬁbrosis, while the expression levels of E-cadherin (H-108, rabbit
polyclonal IgG, diluted 1:100; Santa Cruz Biotechnology, Inc.) and α-smooth muscle
actin (α-SMA; 1A4,mousemonoclonal IgG, diluted 1:100; Dako Cytomation, Denmark)
were assessed immunohistochemically. Deparaﬃnized sections were pretreated by
autoclaving in 10% citric acid buffer (pH 8.0) at 120 °C for 15 min. Following treat-
ment with protein block serum (Dako Cytomation, Kyoto, Japan) for 10 min and
incubation with 2% skim milk for 30 min to block non-speciﬁc reactions, sections
were incubated with primary antibody at 4 °C overnight. The Envision-polymer so-
lution (horseradish peroxidase, HRP, Dako Cytomation) was then applied for 1 h.
Signals were developed in 0.02% 3,3′-diaminobenzidinetetrahydrochloride (DAB) so-
lution containing 0.1%. Sections were then lightly counter stained with hematoxylin
and examined using a ﬂuorescence microscope (Olympus, Tokyo, Japan). The degree
of ﬁbrosis was calculated as a percentage of ﬁbrosis within the whole section in all
samples using a BZ-9000 BZII microscope (Keyence, Osaka, Japan).
Preparation of serum-free conditioned media (SF-CM)
SF-CM was prepared from MKN45 and MKN7 cells as previously reported [12].
Brieﬂy, 1.0 × 106 cells were seeded into 100-mm tissue culture dishes with 10-mL
RPMI, supplemented with 10% FBS and incubated at 37 °C for 3 days. To obtain SF-
CM, the cells were washed twice with PBS and then incubated for 2 days with 5 mL
of serum-free RPMI with or without 100 nM of Angiotensin II. Cells were pre-
treated for 1 h with 1000 nM of candesartan prior to treatment with Angiotensin II
where required. The SF-CMwas harvested, centrifuged at 1500 × g for 5 min, passed
through a ﬁlter (pore size: 0.45 μm) and stored at −80 °C until used.
Phase contrast microscopy
Brieﬂy, HPMCs were seeded into 100-mm tissue culture dishes at 5.0 × 104 cells
in RPMI growth medium with 10% FBS. The HPMCs in cultures were treated with
SF-CM or left untreated (control) for 24 h and morphological changes were visual-
ized by phase contrast microscopy. The images were collected using a Nikon inverted
microscope (Nikon Corp., Japan).
MTT assay
The effect of Angiotensin II and ARB on the proliferative capacity of MKN45 cells
was quantiﬁed using the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay. Brieﬂy, MKN45 cells were seeded in 96-well plates at 4 × 103
cells per well in RPMI growthmediumwith 10% FBS and incubated overnight at 37 °C
in a humidiﬁed environment containing 5% CO2. Following incubation, the super-
natant was discarded and replacedwith fresh serum-freemedium containing different
concentrations (1–100 nM) of Angiotensin II. When required, candesartan (1–
1000 nM) was added 1 h before Angiotensin II treatment to ensure that the
proliferative effect caused by Angiotensin II occurred via the AT1 receptor. At 48 h
post-treatment, the supernatant was discarded and MTT solution was added to each
well (ﬁnal concentration, 500 μg/mL) and incubated at 37 °C for 3 h. The superna-
tant was then removed and 150 μL of DMSO (Wako, Japan) was added. The absorbance
of the solution was read at 535 nm with a microplate reader (Bio-Rad 550; Bio-
Rad, Japan). Cell viability was calculated as: viability = (absorbance of experimental
wells)/(absorbance of control wells). All experiments were repeated at least three
times.
Enzyme-linked immunosorbent assay (ELISA)
The concentration of TGF-β1 in the SF-CM was measured using an ELISA assay
(Quantikine, R&D Systems, Wiesbaden, Germany) according to the manufacturer’s
instructions.
Western blotting
Approximately 5 × 106 cells were lysed in RIPA buffer containing 1% protease in-
hibitor cocktail (Sigma-Aldrich, Inc.). Protein from each sample was loaded onto 12.5%
SDS-PAGE gels and subjected to electrophoresis. Proteins were transferred to a PVDF
membrane (Bio-Rad, USA) and blocked with blocking solution (0.1% Tween-20; EZ
Block ATTO Corporation, Japan) at room temperature for 30 min. Blots were incu-
bated overnight at 4 °C with each primary antibody (see below). The blots were then
incubated for 1 h with appropriate HRP-conjugated secondary antibodies. The
immunoblots were visualized using an ECL Plus Western blotting detection system
(GE Healthcare Japan Ltd., Japan) and the Light-Capture system (ATTO). To ensure
equal protein loading, β-actin levels were measured using an anti-β-actin mono-
clonal antibody (AC-15, mouse monoclonal IgG, diluted 1:10,000; Sigma). The
following primary antibodies were used: AT-1 (N-10, rabbit polyclonal IgG, diluted
1:500; Santa Cruz Biotechnology, Inc.), E-cadherin (H-108, rabbit polyclonal IgG, diluted
1:1000; Santa Cruz Biotechnology, Inc.), α-SMA (1A4, mouse monoclonal IgG, diluted
1:5000; Dako Cytomation, Denmark), TGF-β1 (V, mouse polyclonal IgG, diluted 1:500;
Santa Cruz Biotechnology, Inc.) and anti-β-actin.
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Immunoﬂuorescence
For visualization of E-cadherin and α-SMA in HPMCs, cells were grown on 4-well
collagen type I-coated culture slides (BD BioCoat) at 1.0 × 103 cells, incubated
overnight, ﬁxed in a mixture of methanol and acetone (1:1) for 10 min and then in-
cubated with E-cadherin and α-SMA antibodies (each diluted 1:100) at 4 °C overnight.
Following three PBS washes, slides were incubated with anti-mouse IgG-Alexa Fluor®
488 and anti-rabbit IgG-Alexa Fluor® 546 (1:400 dilution; Molecular Probes/
Invitrogen, USA) for 1 h at room temperature. Slides were then incubatedwith Hoechst
33258 for 5 min to aid nuclear visualization and mounted with propyl gallate con-
taining phenylenediamine under glass coverslips. The slides were observed with an
immunoﬂuorescence microscope (BX50/BX-FLA; Olympus, Japan).
Statistical analysis
All data are expressed as mean ± SD. Statistical analyses were conducted using
the SPSS statistical software, version 11.0 (SPSS). Comparisons of drug effects were
made using one-way analysis of variance (ANOVA) or Student’s t-test. A p-val-
ue < .05 was considered signiﬁcant.
Results
Effect of ARB in subcutaneous xenograft models
To determine whether ARB could be evaluated for anti-
proliferative and anti-ﬁbrotic activity in vivo, ARB (candesartan
10mg/kg) was delivered orally to female nude mice with tumor xe-
nografts (Fig. 1). Tumors derived fromMKN45 cells co-cultured with
HPMCs without administration of candesartan were signiﬁcantly
larger than those from MKN45 cells alone when measured at day
28 (p = .003). This was consistent with results from our previous study
[25]. Furthermore, tumors derived from MKN45 cells co-cultured
with HPMCs were signiﬁcantly smaller in the candesartan treat-
ment group compared with those in the untreated group as early
as day 20 (p = .004). Therefore, candesartan suppressed tumor growth
of cells derived from MKN45 and HPMC co-cultures.
Histological examination of xenograft tumors
Fibrotic areas in tumors derived from MKN45 cells co-cultured
with HPMCs were signiﬁcantly larger than those in tumors from
MKN45 cells alone (Fig. 2A, B). We conﬁrmed the implantation of
the subcutaneous tumors and HPMCs by labeling cells using a PKH26
cell linker kit (Fig. 2C). MKN45 cells co-cultured with HPMCs also
possessed increased α-SMA expression and decreased E-cadherin
expression (Fig. 2D, E). Conversely, tumors from the candesartan
treatment group exhibited increased E-cadherin expression, and de-
creased α-SMA expression when compared with untreated tumors
in the co-culture groups (Fig. 2A–E.). Furthermore, Azan staining re-
vealed that ﬁbrotic areas within tumors of the candesartan group
were signiﬁcantly smaller (Fig. 2F). This suggests that candesartan
was responsible for the suppression of EMT and ﬁbrosis in the tumors
from treated mice.
AT1 receptor expression in human gastric cancer cell lines
We examined three human gastric cancer cell lines for the pres-
ence of the AT1 receptor byWestern blot analysis. All gastric cancer
cell lines expressed AT1 receptor protein as shown in Fig. 3.
The inﬂuence of Angiotensin II and ARB on cellular proliferation
To quantitate the effects of Angiotensin II and ARB on the growth
of human gastric cancer cells the MTT assay was employed. Pro-
liferation of MKN45 cells was signiﬁcantly increased following
Fig. 1. (A) Candesartan inhibits growth of tumors derived from MKN45 and HPMC co-cultures. Tumor volume was measured every fourth day. Results are expressed as the
means ± SD (n = 10). (B) Representative images depict the macroscopic appearance of the tumors at day 28. MKN45 ARB(−): MKN45 without candesartan, MKN45+HPMC
candesartan(−): co-culture of MKN45 and HPMCs without candesartan, MKN45+HPMC candesartan(+): co-culture of MKN45+HPMCs with 10 mg/kg candesartan, a) p < .01
vs. MKN45 candesartan(−) b) p < .01 vs. MKN45+HPMC candesartan(+).
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treatment with 100 nM Angiotensin II (p = .016, Fig. 4A). Further-
more, pretreatment of cells with 1000 nM of candesartan or 500 nM
of telmisartan for 1 h completely inhibited the Angiotensin II-
induced proliferative response (candesartan; p = .001, telmisartan;
p = .036, Fig. 4B). As neither candesartan nor telmisartan (0.1–
1000 nM) had a cytotoxic effect on MKN45 cells as determined by
MTT assay (data not shown), these ﬁndings demonstrate that the
inhibition of Angiotensin II by a speciﬁc AT1 receptor antagonist
could reduce cellular proliferation.
The effect of SF-CM from MKN45 cells on HPMC cell morphology
Control HPMCs without SF-CM treatment grew as a monolayer
of polygonal and cobblestone-like cells (Fig. 5A). In contrast, HPMCs
treated with SF-CM of MKN45 cells demonstrated the elongated
spindle-shaped morphology characteristic of ﬁbroblasts (Fig. 5B).
Similar phenotypic changes were observed with treatment using
SF-CM from cells treated with Angiotensin II (Fig. 5C). HPMCs with
Fig. 2. Growth and EMT is inhibited in MKN45-HPMC co-culture-derived tumors
on mice treated with candesartan. (A) Histological examination using H&E stain-
ing. (B) Fibrotic tissue as determined by Azan staining of subcutaneous xenograft
tumors 28 days after inoculation. (C) Fluorescence microscopy investigating im-
plantation of HPMCs. Red indicates labeled HPMCs. Immunohistochemical
examination of (D) E-cadherin and (E) α-SMA in subcutaneous xenograft tumors (orig-
inal magniﬁcations ×200). (F) The ﬁbrotic area was measured and shown as a
percentage (ﬁbrotic area/whole section area) of that in (B) *p < .01. (For interpreta-
tion of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
Fig. 3. Three gastric cancer cell lines express AT1 receptor. Western blot analysis
demonstrating expression of the AT1 receptor in all three gastric cancer cell lines.
Fig. 4. Angiotensin II-induced proliferation of MKN45 cells is inhibited by ARBs. (A)
The proliferation of MKN45 cells treated with increasing doses of Angiotensin II was
measured by MTT assay. (B) Cells were then pretreated with increasing doses of
candesartan prior to addition of Angiotensin II and measurement of proliferation
by MTT assay at 48 hours. Results are mean ± SD of three experiments.*p < .05.
49M. Okazaki et al./Cancer Letters 355 (2014) 46–53
SF-CM of these phenotype changes were attenuated by pretreat-
ment of MKN45 cells with 1000 nM candesartan and 1000 nM
telmisartan prior to harvesting SF-CM (Fig. 5D, E). We selected
candesartan for the following experiments because it is a more se-
lective ARB than telmisartan, which also affects peroxisome
proliferator-activated receptor-γ (PPAR-γ) [38,39].
TGF-β1 expression
To investigate whether Angiotensin II and candesartan inﬂu-
ence the expression of TGF-β1, we used an ELISA and Western
blotting to measure levels of TGF-β1 in the culture media. Treat-
ment of MKN45 and MKN7 with Angiotensin II elevated the level
of TGF-β1, while pretreatment of cells with candesartan effective-
ly inhibited this response (Fig. 6).
Examination of EMT marker expression in HPMCs
Immunoﬂuorescence staining of HPMCs cultured with SF-CM
from MKN45 cells treated with Angiotensin II demonstrated ex-
pression of the mesenchymal marker α-SMA in the cell membrane
and cytoplasm, with no nuclear staining observed (Fig. 7A). Con-
versely, HPMCs cultured with SF-CM from MKN45 cells pretreated
with candesartan had a markedly diminished presence of α-SMA
signal in the cytoplasm (Fig. 7A). Western blotting conﬁrmed the
immunoﬂuorescence study, with increased α-SMA expression and
decreased E-cadherin expression found in HPMCs cultured with SF-
CM fromMKN45 cells treated with Angiotensin II (Fig. 7B). Western
blotting also detected diminished α-SMA and increased E-cadherin
expression was identiﬁed in HPMCs cultured with SF-CM from
MKN45 cells pretreated with candesartan (Fig. 7B). Blots were re-
probed for β-actin to ensure equal protein loading in each lane.
Results are representative data from three separate experiments.
Discussion
We used candesartan and telmisartan as ARBs in this study.
However, we chieﬂy used candesartan because telmisartan is also
a partial agonist of PPAR-γ [38,39]. Our data reveal that the
candesartan can signiﬁcantly suppress tumor proliferation and ﬁ-
brotic changes in a subcutaneous xenograft model. Furthermore, we
have demonstrated that Angiotensin II induces TGF-β1 expression
and that ARB suppresses this stimulation in the gastric cancer cell
line MKN45. SF-CM from MKN45 cells and exposure to Angioten-
sin II induced an EMT-like change in HPMCs, while pretreatment
with candesartan impaired this change.
Angiotensin II is a main effector peptide in the renin–angiotensin
system (RAS) and also plays a fundamental role as a vasoconstric-
tor in controlling cardiovascular function and renal homeostasis [40].
Recent studies have shown that a local RAS can exist in malignant
tumor tissue, with Angiotensin II potentially acting as a key factor
for promotion of tumor growth and metastasis via the AT1 recep-
tor [41]. Arakawa and Maruta have demonstrated that trypsin
generates Angiotensin II from circulating angiotensinogen in the
absence of angiotensin converting enzyme (ACE) at a weakly acidic
pH of 5.5 [42]. In acidic tissues, such as those found in gastric cancer,
tryptase and trypsinogen derived from migrating mast cells may
convert angiotensinogen to Angiotensin II. We have further sug-
gested that circulating angiotensinogen in the blood is converted
directly to Angiotensin II by trypsin in the tumor microenviron-
ment at the weakly acidic pH found with anaerobic glycolysis [43].
We have also previously demonstrated that gastric cancer and in-
trahepatic cholangiocarcinoma tissue have higher levels of
Angiotensin II than normal tissues [30,31]. Furthermore, gastric
cancer tissue and cell lines alike have been found to express the AT1
receptor in both the current and previous studies [30,44]. Local tissue
RAS signaling is potentially able to up-regulate the Angiotensin II/
AT1 receptor pathway in an autocrine fashion, resulting in
Angiotensin II-induced progression of gastric cancermalignancy [44].
Lever and colleagues reported the ﬁrst clinical evidence that a
long-term Angiotensin II blockade may be protective against car-
cinogenesis [45]. We have previously reported that Angiotensin II
has the potential to enhance cell proliferation and impair apopto-
sis by promoting ERK1/2 and NF-κB activation and overexpression
[30]. ERK1/2 transduces extracellular signals to the nucleus and in-
creases the expression of genes involved in cellular proliferation [46].
Meanwhile, the transcription factor NF-κB regulates the expres-
sion of numerous genes, including survival factors and cell growth
Fig. 5. SF-CM from MKN45 cells induces morphological changes in HPMC cells that are impaired by pretreatment of cells with candesartan and telmisartan. Representa-
tive images of morphological changes induced after culture of HMPCs with SF-CM HPMCs cultured in control medium (A), SF-CM of MKN45 (B), SF-CM from MKN cells
treated with Angiotensin II (C), or SF-CM from MKN45 cells pretreated with candesartan (D) and telmisartan (E) prior to Angiotensin II. Images were obtained by phase
contrast microscopy at magniﬁcation, × 40.
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regulatory molecules [47,48] Hence, the blockade of Angiotensin II
has been considered a potential target for anti-proliferative therapy
in tumorigenesis. Our ﬁnding that ARB suppresses Angiotensin II-
induced tumor growth in vitro and in vivo supports this.
Fibrosis is a common feature of both peritoneal dissemination
and chronic renal disease. Numerous studies have demonstrated that
the Angiotensin II/AT1 receptor axis contributes to renal ﬁbrosis
through endogenous production of TGF-β1 [49,50]. Angiotensin II
induces expression of the TGF-β1 activator thrombospondin-1 via
the AT1 receptor, thereby mediating activation of latent TGF-β1
[51,52]. TGF-β1 then signals to the nuclei through activation of the
Smad pathway, and promotes EMT in tubuloepithelial cells [50].
The development of peritoneal dissemination is a multistep
process. Cancer cells within the peritoneal cavity can attach to HPMCs
and induce an EMT-like change by release of TGF-β1 [17,53]. Such
spindle-shaped HPMCs can then facilitate adhesion of cancer cells
to the submesothelial basement membrane [26]. Furthermore, ac-
tivated HPMCs are a source of CAFs through transformation to a
myoﬁbroblast-like phenotype. These CAFs can inﬁltrate the
submesothelial basement membrane together with cancer cells and
promote the processes of proliferation and ﬁbrosis [25]. Thereaf-
ter, locally synthesized Angiotensin II stimulates cellular proliferation
and ﬁbrosis through AT1 receptor activation and TGF-β1 signals. In
this cascade, TGF-β1 is produced by both cancer cells and CAFs [21].
This interaction between gastric cancer cells and CAFs through the
Angiotensin II/AT1 receptor axis likely has autocrine and paracrine
synergistic effects on tumor progression and ﬁbrosis. As a result, peri-
toneal dissemination progresses rapidly with extensive stromal
ﬁbrosis, contributing to the poor prognosis associated with dis-
seminated gastric cancer.
Inhibiting the effects of Angiotensin II and TGF-β1 described above
is important for the attenuation of tumor proliferation and ﬁbro-
sis. Previous reports have shown that TGF-β1 neutralizing antibodies
and TGF-β1 receptor kinase inhibitors can suppress EMT and reduce
stromal ﬁbrosis [17,54]. However, these agents cannot be admin-
istrated to patients with various cancer and ﬁbrotic diseases because
TGF-β1 and its receptors are almost ubiquitously expressed in normal
tissues. This is a major conceptual problemwith the long-term clin-
ical use of these agents as there is a high likelihood of adverse side
effects because of disruption of the many important roles played
by TGF-β1 in normal tissues [55]. However, as candesartan has been
widely used as a clinical antihypertensive agent without serious side
effects [56], it could potentially be safely used as an anticancer agent.
This current study supports the hypothesis that candesartan offers
a new strategy for peritoneal dissemination through suppression
of both tumor proliferation and ﬁbrosis.
In conclusion, we have shown that candesartan can signiﬁ-
cantly reduce TGF-β1 expression, and suppress tumor cell
proliferation and stromal ﬁbrosis in a mice xenograft tumor model.
Candesartan was effective at a dose rate of 10 mg/kg/day, which is
close to the maximal clinical dose [57]. Targeting the Angiotensin
II signaling pathway may not only impair tumor proliferation, but
may also be a novel, eﬃcient strategy for treating associated tissue
ﬁbrosis. Therefore, combination therapy using ARBs and cytotoxic
Fig. 6. Angiotensin II-induced elevation of TGF-β1 levels in MKN45 and MKN7 cell media is wholly inhibited by pretreatment of cells with candesartan. Levels of TGF-β1
were measured in both the culture media and cells from MKN45 and MKN7 cultures treated with Angiotensin II or pretreated with candesartan as indicated. Results are
mean ± SD of three experiments. (A) MKN45 and (B) MKN7 TGF-β1 levels by ELISA, *p < .01 and (C) Western blot.
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antineoplastic agents could potentially improve the prognosis for
patients with peritoneal dissemination of gastric cancer.
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